dc.contributor.author | Çakal, Beytullah | |
dc.contributor.author | Çakal, Sinem Deniz | |
dc.contributor.author | Karaca, Oǧuz | |
dc.contributor.author | Omaygenç, Mehmet Onur | |
dc.contributor.author | Kızılırmak, Filiz | |
dc.contributor.author | Güneş, Hacı Murat | |
dc.contributor.author | Özcan, Özgür Ulaş | |
dc.contributor.author | İbişoğlu, Ersin | |
dc.contributor.author | Boztosun, Bilal | |
dc.date.accessioned | 2021-04-05T12:15:56Z | |
dc.date.available | 2021-04-05T12:15:56Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Çakal, B., Çakal, S. D., Karaca, O., Omaygenç, M. O., Kızılırmak, F., Güneş, H. M. ... Boztosun, B. (2021). Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice. Minerva Cardioangiologica, 69(3), 261-268. https://dx.doi.org/10.23736/S0026-4725.20.05138-5 | en_US |
dc.identifier.issn | 0026-4725 | |
dc.identifier.issn | 1827-1618 | |
dc.identifier.uri | https://dx.doi.org/10.23736/S0026-4725.20.05138-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/6695 | |
dc.description.abstract | BACKGROUND: Most of the current data regarding the use of bioresorbable scaffolds (BRS) come from everolimus-eluting stent platforms. Adverse events with the everolimus-eluting BRSs which are the most comprehensively characterized BRS, hampered the clinical use of other BRS. There is paucity of published data regarding long term use of novolimus-eluting BRS.METHODS: This study sought to evaluate the performance of novolimus-eluting BRS device at midterm follow-up in real world clinical practice. One hundred and forty four patients (mean age 57.5 ± 9.7 years, 78.5% male) treated with 206 scaffolds between October 2015 and December 2017 were enrolled. A device-oriented composite endpoint (DOCE) comprising cardiac death, target vessel myocardial infarction (TV-MI), clinically driven target lesion revascularization (TLR) and rate of scaffold thrombosis were investigated.RESULTS: During a mean follow-up of 33±9 months, DOCE occured in 9 patients (6.3%) of which cardiac death occured in 2 patients (1.4%), and clinically-driven TLR in 7 patients (4.9%), TV-MI in one patient. Target vessel revascularization (TVR) was observed in nine patients. None of the patients experienced scaffold thrombosis.CONCLUSIONS: The use of novolimus-eluting BRS in this real world population achieved good clinical outcomes. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Edizioni Minerva Medica | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Bioresorbable Vascular Scaffold | en_US |
dc.subject | Percutaneous Coronary Intervention | en_US |
dc.subject | Major Cardiac Events | en_US |
dc.title | Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Minerva Cardioangiologica | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-0230-6575 | en_US |
dc.authorid | 0000-0003-2714-4584 | en_US |
dc.authorid | 0000-0002-4281-0867 | en_US |
dc.authorid | 0000-0003-2995-8792 | en_US |
dc.authorid | 0000-0003-1919-3183 | en_US |
dc.authorid | 0000-0001-5825-8627 | en_US |
dc.authorid | 0000-0003-1516-1811 | en_US |
dc.authorid | 0000-0002-4951-6716 | en_US |
dc.identifier.volume | 69 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 261 | en_US |
dc.identifier.endpage | 268 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.23736/S0026-4725.20.05138-5 | en_US |